Quick Overview.
PT-141 (generic name Bremelanotide) is a synthetic peptide designed specifically to treat sexual dysfunction in both men and women. It is actually a modified version of the tanning peptide Melanotan II. Scientists realized that Melanotan II caused intense sexual arousal, but they didn't want a libido drug that also turned people dark brown. So, they tweaked the molecule to remove the tanning effect, leaving only the pure, centrally-acting libido enhancement. It is FDA-approved for women under the brand name Vyleesi.[1][2]
Drugs like Viagra work in the plumbing. They open up blood vessels in the pelvis so blood can flow in, but you still need to be mentally turned on for them to work. PT-141 works in the brain. It flips a switch in your nervous system that directly causes sexual desire and arousal. It doesn't just fix the plumbing; it turns on the engine.[3]
- Primary Use Case: Treatment of erectile dysfunction (ED) and female hypoactive sexual desire disorder (HSDD).
- Mechanism: A non-selective agonist of the melanocortin receptors (MC3R and MC4R) in the central nervous system.[4]
- Who it is for: Men who do not respond to PDE5 inhibitors (Viagra/Cialis) due to psychological ED, and premenopausal women suffering from low libido.
- Who it is NOT for: People with uncontrolled high blood pressure or severe cardiovascular disease.
Turn this protocol into your actual schedule.
Log every dose, every side-effect, and every PR on one timeline.
The Protocol & Usage Guide.
confidence_tier: well-established
The nausea is the biggest hurdle. For some users, the nausea is so severe that it completely ruins the mood, defeating the purpose of the drug. Furthermore, PT-141 can cause a temporary but significant spike in blood pressure.[5]
Standard Dosing
Note: PT-141 is taken "on-demand," not daily. The FDA recommends no more than 8 doses per month.
| Phase | Dose | Frequency | Timing |
|---|---|---|---|
| Test Dose | 500 mcg (0.5 mg) | Once | To assess nausea tolerance |
| Standard Dose | 1 mg to 1.75 mg | As needed | 1 to 2 hours before sexual activity |
| Maximum Dose | 2 mg | As needed | Do not exceed 2mg in a 24-hour period |
Reconstitution Math (Example for a 10mg vial)
- Add 1 mL of Bacteriostatic Water to the 10mg vial.
- 1 mg dose = 0.10 mL (10 units on an insulin syringe)
- 1.75 mg dose = 0.175 mL (17.5 units on an insulin syringe)
Injection Site Guide
- Where to Inject: Subcutaneous fat in the abdomen or thigh.
Cycle Length & Discontinuation Protocol
- Cycle Length: Used as needed. Do not use more than once per 24 hours, or more than 8 times per month to prevent receptor desensitization.
- Discontinuation: Can be stopped at any time with no withdrawal effects.
Nutritional Support & Recommended Supplements.
confidence_tier: well-established
| Supplement | Rationale | Recommended Dose |
|---|---|---|
| Ginger Root / Zofran | To combat the nausea that occurs shortly after injection. | As needed. |
| L-Citrulline | While PT-141 works in the brain, adding a nitric oxide booster like Citrulline helps the "plumbing" keep up with the brain's demands. | 6-8g before activity. |
Safety, Interactions & Side Effect Management.
confidence_tier: well-established
Side Effect Profile
| Side Effect | Severity | Frequency | Management |
|---|---|---|---|
| Nausea | Moderate | Very Common | Start with a low dose (500mcg) to build tolerance. |
| Flushing/Headache | Mild | Common | Caused by the vascular effects of the drug. Usually passes within an hour. |
| Increased Blood Pressure | Moderate | Occasional | Monitor BP. Do not use if resting BP is high. |
| Focal Hyperpigmentation | Mild | Rare | Darkening of the gums or skin with excessive, frequent use. |
Contraindications
- Absolute: Individuals with uncontrolled hypertension (high blood pressure).
- Absolute: Individuals with a history of cardiovascular disease.
- Absolute: Pregnant or breastfeeding women.
Drug Interactions
- Naltrexone (Oral): SEVERE. PT-141 significantly slows gastric emptying. It can drastically reduce the absorption of oral medications taken at the same time, particularly Naltrexone.[6]
- PDE5 Inhibitors (Viagra/Cialis): Moderate. While often stacked by biohackers, combining them increases the risk of priapism (an erection lasting longer than 4 hours) and severe blood pressure fluctuations.
Common Stacks & Combinations.
confidence_tier: community
| Stack | Goal | Rationale |
|---|---|---|
| PT-141 + Cialis (Low Dose) | The Ultimate ED Stack | PT-141 provides the mental arousal and central nervous system signal; Cialis ensures the blood vessels are fully dilated to receive the signal. Use caution regarding blood pressure. |
Body Composition & Training Guide.
confidence_tier: community
- The "Delayed" Effect: Unlike Viagra, which works in 30 minutes, PT-141 takes time to cross the blood-brain barrier and activate the nervous system. Many users report the best effects happen 4 to 6 hours after injection.
- The Nasal Spray Failure: Many research chemical sites sell PT-141 as a nasal spray. The community consensus is that the nasal spray is highly ineffective due to poor absorption. Subcutaneous injection is the only reliable method.
Storage, Handling & Accessibility.
confidence_tier: well-established
- Storage (Lyophilized): Store in the freezer (-20°C) for up to 3-5 years, or in the fridge (2-8°C) for 1-2 years.
- Storage (Reconstituted): Must be stored in the fridge (2-8°C). Good for 14-21 days.
- WADA Status: Not explicitly banned, but falls under unapproved substances for men.
- Cost & Accessibility: Widely available from research chemical vendors, usually ~$30 - $50 per 10mg vial.
Bloodwork Monitoring Guide.
confidence_tier: well-established
There are no specific blood markers required for PT-141 use.
- Cardiovascular Monitoring: Regular blood pressure monitoring is the most critical safety check for this compound.
Comparison to Similar Compounds.
confidence_tier: well-established
| Feature | PT-141 (Bremelanotide) | Melanotan II (MT-2) | Sildenafil (Viagra) |
|---|---|---|---|
| Mechanism | Central (Brain) | Central (Brain) + Skin | Peripheral (Blood Vessels) |
| Primary Effect | Libido / Arousal | Tanning + Libido | Erection Quality |
| Nausea | Moderate | Severe | None |
| Tanning Effect | Very Low | Extreme | None |
Deep Dive (For Advanced Researchers).
confidence_tier: well-established
Mechanism of Action
Bremelanotide (PT-141) is a synthetic, cyclic heptapeptide. It is an active metabolite of Melanotan II. Its amino acid sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH.[7]
The only structural difference between Melanotan II and PT-141 is the C-terminus. Melanotan II has an amide group (-NH2) at the C-terminus, while PT-141 has a hydroxyl group (-OH). This seemingly minor change drastically alters the peptide's receptor binding affinity.[8]
Cellular Pathways
- Receptor Selectivity: While Melanotan II binds strongly to MC1R (tanning), MC3R, and MC4R, the hydroxyl modification in PT-141 significantly reduces its affinity for the MC1R receptor in the skin. It acts primarily as a non-selective agonist of the MC3R and MC4R receptors.[4]
- The MC4R Pathway: The pro-sexual effects of PT-141 are mediated almost entirely through the activation of MC4R receptors located in the hypothalamus and the limbic system of the brain.[9]
- The Neural Cascade: Activation of central MC4R neurons sends descending signals through the spinal cord to the pelvic splanchnic nerves. This triggers the release of nitric oxide (NO) and vasoactive intestinal peptide (VIP) directly in the erectile tissues of both men and women, causing engorgement and arousal independent of the cardiovascular system.[3]
Clinical Trial Summary
- Female HSDD (Vyleesi): In Phase III clinical trials (RECONNECT), premenopausal women with HSDD who took 1.75mg of bremelanotide reported a statistically significant increase in sexual desire and a decrease in distress related to low sexual desire compared to placebo. The FDA approved it in 2019.[1][10]
- Male Erectile Dysfunction: Palatin Technologies originally developed PT-141 for men. In Phase II trials, it was highly effective at inducing erections in men who did not respond to Viagra (because it bypasses the vascular system and works on the nervous system). However, the FDA halted the male trials in 2007 because a small number of men experienced significant spikes in blood pressure. Palatin pivoted to women (who experienced less severe BP spikes) to get the drug approved.[11]
Synergy & Antagonism Analysis
- Gastric Emptying: Activation of the melanocortin system slows gastric motility. This is why PT-141 causes nausea and why it can delay the absorption of oral drugs. Taking an oral PDE5 inhibitor (like Viagra) at the exact same time as a PT-141 injection may result in the Viagra taking much longer to kick in than usual.[6]
Frequently Asked Questions (FAQ).
confidence_tier: community
Q: Why does it make me feel sick to my stomach? A: The receptors in your brain that control sexual arousal (MC4R) are located right next to the receptors that control nausea and satiety. When the peptide activates the arousal receptors, it accidentally triggers the nausea receptors as well.
Q: Is it better than Viagra? A: They do different things. Viagra makes it physically easier to get an erection, but you still have to be "in the mood." PT-141 puts you "in the mood" by directly stimulating your brain. For men with psychological ED or low libido, PT-141 is often superior.
Q: Can I use the nasal spray instead of injecting it? A: You can, but it is highly inefficient. The peptide is too large to easily cross the nasal mucosa. You will absorb less than 20% of the drug, making it a waste of money. Subcutaneous injection is the only reliable method.
Q: Will it make me tan? A: It is highly unlikely. The molecule was specifically designed to remove the tanning effect of Melanotan II. However, if you abuse it at massive doses daily, some slight darkening of the skin can occur.
International Regulatory Status.
confidence_tier: well-established
| Agency | Status | Notes |
|---|---|---|
| US FDA | Approved (Women) | Approved as Vyleesi for HSDD in women. Unapproved for men. |
| WADA | Unapproved | Not explicitly banned, but falls under unapproved substances for men. |
| UK MHRA | Unapproved | Not licensed for medical use. |
| EU EMA | Unapproved | Not licensed for medical use. |
Decision Tree.
confidence_tier: community
[Goal: Treat Low Libido or Psychological ED?]
|
+-- Do you have high blood pressure or cardiovascular disease?
|
+-- (Yes) -> STOP: Do not use PT-141.
|
+-- (No) -> Are you willing to manage potential nausea?
|
+-- (No) -> Stick to PDE5 inhibitors (Viagra/Cialis).
|
+-- (Yes) -> Inject 1mg to 1.75mg subcutaneously 2 hours before activity.
Do not exceed 8 doses per month.Schema.org Data.
{
"@context": "https://schema.org",
"@type": "MedicalEntity",
"name": "Bremelanotide",
"alternateName": ["PT-141", "Vyleesi"],
"description": "A synthetic melanocortin receptor agonist that acts centrally to increase sexual desire and arousal. FDA-approved for HSDD in women.",
"legalStatus": {
"@type": "DrugLegalStatus",
"description": "FDA-approved for women (Vyleesi). Unapproved for men; available as a research chemical."
}
}What we cited.
- Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. doi:10.1097/AOG.0000000000003500
- Dhillon S, et al. Bremelanotide: First Approval. Drugs. 2019;79(14):1599-1606. doi:10.1007/s40265-019-01187-w
- Wessells H, et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000;12 Suppl 4:S74-S79. doi:10.1038/sj.ijir.3900582
- Shadiack AM, et al. Melanocortins in the treatment of male and female sexual dysfunction. Curr Top Med Chem. 2007;7(11):1137-1144. doi:10.2174/156802607780906681
- Mayer D, et al. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. Ann Pharmacother. 2020;54(7):684-690. doi:10.1177/1060028019899152
- FDA Prescribing Information for VYLEESI (bremelanotide injection).
- Diamond LE, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16(1):51-59. doi:10.1038/sj.ijir.3901139
- Hadley ME, et al. Discovery and development of novel melanogenic drugs. Melanotan-I and -II. Pharm Biotechnol. 1998;11:575-595. doi:10.1007/0-306-47384-4_25
- Pfaus JG, et al. The role of melanocortin receptor agonists in the treatment of sexual dysfunction. Int J Impot Res. 2004;16(1):18-24. doi:10.1038/sj.ijir.3901136
- Cipriani S, et al. An evaluation of bremelanotide injection for the treatment of premenopausal women with generalized hypoactive sexual desire disorder. Expert Opin Pharmacother. 2023;24(1):15-23. doi:10.1080/14656566.2022.2130141
- Rosen RC, et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004;16(2):135-142. doi:10.1038/sj.ijir.3901200